NBD AI Bulletin -- Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SH 603707, close price: 30.74 yuan) on September 17 announced that the Company's controlling shareholder and actual controller Xie Juhua on September 16 pledged 12.5 million shares.

The 2020 annual report shows that Nanjing King-Friend Biochemical Pharmaceutical's main business is the pharmaceutical manufacturing industry, accounting for 99.88% of revenue.

Nanjing King-Friend Biochemical Pharmaceutical's general manager and chairman is Tang Yongqun, male, 46 years old, US citizen, master's degree, engineer, senior engineer.

(By Gao Han)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.